Want to see OTLC full AI Analyst Report?
Top Page
Oncotelic Therapeutics
(OTC:OTLC)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.04
▼(-10.00% Downside)
Action:Reiterated
Date:08/05/26
The score is held down primarily by very weak financial performance (minimal revenue, persistent losses, and ongoing cash burn) and a generally bearish technical setup (below longer-term moving averages with negative MACD). Valuation screens low on P/E but is less meaningful given the weak fundamentals, while corporate events add near-term dilution risk from convertible financing with only partial strategic offsets.
Positive Factors
Low reported leverage
Reported debt-to-equity near 0.06 indicates modest leverage, which reduces near-term solvency and interest-burden risk. This durable balance-sheet characteristic gives the company more flexibility to manage short-term obligations and negotiate financing without immediate distress, aiding operational continuity.
Negative Factors
Minimal revenue and persistent losses
Near-zero recurring revenue and sustained operating losses indicate lack of commercial traction and no scalable revenue base. Over a multi-month horizon this undermines self-sustainability, limits reinvestment capacity, and means value depends primarily on R&D outcomes rather than stable cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low reported leverage
Reported debt-to-equity near 0.06 indicates modest leverage, which reduces near-term solvency and interest-burden risk. This durable balance-sheet characteristic gives the company more flexibility to manage short-term obligations and negotiate financing without immediate distress, aiding operational continuity.
Read all positive factors
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.19M
Dividend YieldN/A
Average Volume (3M)410.07K
Price to Earnings (P/E)<0.1
Beta (1Y)-0.05
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.58
Shares Outstanding443,615,720
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncotelic Therapeutics Business Overview & Revenue Model
Company Description
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound de...
How the Company Makes Money
null...
Oncotelic Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 70.00K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 70.00K | -12.84K | -61.51K |
| EBITDA | 198.05B | -3.55M | -7.16M | -5.60M | -9.06M |
| Net Income | 249.28M | -4.52B | -7.90M | 17.82M | -11.39M |
Balance Sheet | |||||
| Total Assets | 10.00T> | 26.68M | 30.01M | 36.12M | 23.61M |
| Cash, Cash Equivalents and Short-Term Investments | 88.86B | 86.13K | 170.41K | 241.45K | 568.77K |
| Total Debt | 16.27T | 13.09M | 12.57M | 11.26M | 8.99M |
| Total Liabilities | 10.00T> | 19.20M | 18.40M | 16.92M | 15.45M |
| Stockholders Equity | 10.00T> | 8.25M | 12.13M | 19.41M | 7.96M |
Cash Flow | |||||
| Free Cash Flow | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Operating Cash Flow | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.39T | 656.00K | 1.25M | 1.13M | 4.53M |
Oncotelic Therapeutics Technical Analysis
Neutral
0.04
Price Trends
0.04
Negative
0.04
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
49.05
Neutral
63.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Neutral. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.05 is Neutral, neither overbought nor oversold. The STOCH value of 63.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OTLC.
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics disclosed 38 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncotelic Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $37.88M | 0.68 | -560.64% | ― | -32.64% | 56.66% | |
47 Neutral | $30.74M | -0.75 | 4092.98% | ― | ― | 16.33% | |
44 Neutral | $76.00M | -1.83 | -284.80% | ― | ― | 16.55% | |
43 Neutral | $33.85M | -3.74 | -14.15% | ― | ― | 43.67% | |
42 Neutral | $17.19M | 0.07 | -38.38% | ― | ― | ― | |
42 Neutral | $33.56M | -1.81 | -198.35% | ― | ― | 21.67% |
* Healthcare Sector Average
OTLC
Oncotelic Therapeutics
0.04
-0.01
-23.91%
GRCE
Grace Therapeutics
2.18
-0.79
-26.60%
LTRN
Lantern Pharma
2.75
-2.39
-46.50%
CALC
CalciMedica
0.80
-2.21
-73.50%
ELUT
Elutia
0.87
-1.10
-55.74%
MAIA
MAIA Biotechnology, Inc.
1.36
-0.16
-10.53%
Oncotelic Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Announces New Convertible Note Financing Agreement
Negative
Aug 4, 2026
On August 3, 2026, Oncotelic Therapeutics entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a $178,410 convertible promissory note with a 12% original issue discount and 12% annual interest. The note can be con...
Business Operations and StrategyExecutive/Board Changes
Oncotelic Therapeutics Grants Performance-Based Restricted Stock Units
Positive
Jul 15, 2026
On July 10, 2026, Oncotelic Therapeutics, Inc. approved the grant of 17,796 restricted stock units to its directors, officers, employees, and advisors, each RSU convertible into one share of Series A Convertible Preferred Stock and ultimately into...
Business Operations and StrategyRegulatory Filings and Compliance
Oncotelic Therapeutics Provides Internal Corporate Update Presentation
Neutral
Jul 15, 2026
On July 13, 2026, Oncotelic Therapeutics, Inc. delivered a corporate presentation to its employees, directors, officers and advisors, outlining company information in a formal setting. The materials were furnished to stakeholders through a Form 8-...
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Therapeutics Enters New Convertible Note Financing
Neutral
Jun 29, 2026
On June 23, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a $178,410 convertible promissory note carrying a 12% original issue discount and 12% annual interest, maturing...
Business Operations and StrategyM&A Transactions
Oncotelic Secures Lunai Stake and IP License Rights
Positive
May 5, 2026
On May 1, 2026, Oncotelic Therapeutics completed a merger in which its affiliate Holdings was merged into Merger Sub, making Merger Sub a wholly owned subsidiary of Lunai, and in exchange Oncotelic received five shares of Lunai’s Series B pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.